Is Solid Biosciences (SLDB) Undervalued Following Its Russell Growth Index Additions?

Solid Biosciences (SLDB) has just been added to several Russell growth benchmarks, including the Russell 2000 Growth and Russell 3000 Growth indices, an index reshuffle that can influence how some investors view the stock.

See our latest analysis for Solid Biosciences.

These index additions come after a strong run in Solid Biosciences' share price, with a 30 day share price return of 66.42% and a year to date share price return of 104.59%. The 1 year total shareholder return of 112.79% contrasts with a 5 year total shareholder return that is significantly lower, indicating that recent momentum has picked up after a weaker longer term record.

If you are looking for other high growth stories in related areas like drug discovery and treatment platforms, this could be a good time to check out 40 healthcare AI stocks

After Solid Biosciences' sharp move and fresh inclusion in several Russell growth indices, the question now is whether the current price still offers an appealing balance between risk and potential reward as valuation comes under the spotlight.

SWS DCF valuation: what it suggests for Solid Biosciences

Our DCF model estimates a future cash flow value of $140.99 per share for Solid Biosciences, compared with the last close of $11.15. This implies a very large discount if those projections play out.

The SWS DCF model works by projecting the cash flows Solid Biosciences could generate in the future and then discounting those back to today using a required return. This approach focuses on the company’s potential to create value over time rather than its current reported revenue or earnings. This can be useful for a biotech that is still in the development stage.

For Solid Biosciences, which is currently unprofitable with reported revenue of $0 and a net loss of $191.78 million, the DCF framework places more weight on expected future revenue growth than on current financials. That aligns with the broader biotech sector, where investors often focus on the probability and timing of clinical and commercial milestones when assessing long term value.

Look into how the SWS DCF model arrives at its fair value.

Result: DCF Fair value of $140.99 (UNDERVALUED)

However, Solid Biosciences still faces clear risks, including its current net loss of $191.78 million and the clinical uncertainty across its early stage pipeline.

Find out about the key risks to this Solid Biosciences narrative.

Another view on Solid Biosciences’ valuation

Price-based metrics tell a different story from the SWS DCF model. Solid Biosciences trades on a P/B ratio of 2.9x, slightly above the US biotech industry average of 2.8x but below the peer average of 5.8x. This suggests the market is already pricing in some optimism but not the most bullish scenario.

The gap between the industry and peer benchmarks points to a mix of valuation risk and possible opportunity. The balance depends on how investors weigh Solid Biosciences’ unprofitable status against its forecast revenue growth and early-stage pipeline.

See what the numbers say about this price — find out in our valuation breakdown.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Solid Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Curious how Solid Biosciences compares when you weigh the concerns against the potential upside? Take a closer look at the full picture with 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Solid Biosciences?

If Solid Biosciences has sharpened your focus, this is the moment to cast a wider net and uncover other stocks that could suit your style and goals.

• Spot opportunities that the crowd might be overlooking by checking our screener containing 18 high quality undiscovered gems.
• Prioritize strength and resilience by reviewing companies in the solid balance sheet and fundamentals stocks screener (47 results).
• Dial back risk without stepping away from the market using the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com